Maher Bishara, MD
Nephrology · Houston, TXNPI 1689650970
Payments from drug & device makers
Across 309 payments — averaging $1581.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$420K
- Vertex$61K
- AstraZeneca$2K
- Bayer$638
- Otsuka America Pharmaceutical, Inc.$570
- GSK$504
- plus $4K from 28 others
Across 1 payment — averaging $110,304 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$110K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 2 | $420,036 |
| Vertex | 1 | $60,738 |
| AstraZeneca(2 entities) | 54 | $1,619 |
| Bayer | 32 | $638 |
| Otsuka America Pharmaceutical, Inc. | 24 | $570 |
| GSK | 11 | $504 |
| Mallinckrodt Hospital Products Inc. | 22 | $479 |
| Amgen(2 entities) | 25 | $460 |
| Travere Therapeutics, Inc. | 11 | $379 |
| Novo Nordisk | 6 | $338 |
| Novartis | 13 | $317 |
| ANI Pharmaceuticals, Inc. | 11 | $221 |
| Fresenius USA Marketing, Inc. | 13 | $217 |
| Johnson & Johnson | 9 | $211 |
| Mallinckrodt Enterprises LLC | 12 | $210 |
| Aurinia Pharma U.S., Inc. | 5 | $205 |
| Calliditas Therapeutics US Inc. | 8 | $154 |
| Lilly USA, LLC | 7 | $149 |
| Vifor Pharma, Inc. | 8 | $129 |
| OPKO Pharmaceuticals, LLC | 9 | $127 |
| Mylan Specialty L.p. | 1 | $123 |
| Akebia Therapeutics Inc | 7 | $122 |
| Nxstage Medical, Inc. | 1 | $119 |
| Corcept Therapeutics | 1 | $111 |
| Apellis Pharmaceuticals, Inc. | 2 | $64 |
| Sanofi | 3 | $62 |
| Boehringer Ingelheim | 2 | $48 |
| Ardelyx, Inc. | 2 | $46 |
| Medtronic | 1 | $40 |
| Recor Medical Inc | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $35 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Scpharmaceuticals Inc. | 1 | $21 |
| Pfizer | 1 | $19 |
How this compares
$488,570 in reported general payments places this provider in the 95th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Houston
- Sreedhar MandayamHouston$7M
- Marializa BernardoHouston$4.2M
- Stephen FademHouston$2.4M
- Biruh WorkenehHouston$1.8M
- Rahul PandeyHouston$1.6M
- Christopher KwohHouston$928K
- George NassarHouston$772K
- June YaoHouston$651K
- Wolfgang WinkelmayerHouston$462K
- Dana MitchellHouston$460K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.